Research programme: macrocyclic peptide therapeutics - AstraZeneca/Syneron Bio
Alternative Names: Macrocyclic peptide therapeuticsLatest Information Update: 16 Jul 2025
At a glance
- Originator AstraZeneca; Syneron Bio
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Metabolic disorders